Fate Therapeutics, Inc.
NASDAQ:FATEBiotechnology
-$0.00 today
- Market cap
- $122.39M
- Beta
- 2.52
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.08
Volume 1.87M
Average 2.92M
FATE Sales of Investments
Cash received from selling or redeeming investments.
Fate Therapeutics, Inc.NASDAQ: FATE
Sales of Investments · Q1 FY2026 · quarter ended Mar 2026
Sales of investments declines year over year
Q1 FY2026 sales of investments of $52.56M fell 43.2% year over year, behind the -14.9% change in trailing-twelve-month sales of investments. Sequentially, it fell 20.8% from the prior quarter. Over 3 fiscal years it compounded at -19.9% a year.
Context
- Sales of investments amounted to 4693.0% of revenue in FY2025, up 2267.0 pp from a year earlier.
- Sales of investments increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -43.2% toward the trailing-twelve-month pace of -14.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 311.9M USD
- Year-over-year change
- -5.7%
- 4-year CAGR
- -18.1%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 311.9M | -5.7% |
| FY2024 | 2024-12-31 | 330.7M | -30.8% |
| FY2023 | 2023-12-31 | 477.63M | -21.3% |
| FY2022 | 2022-12-31 | 607.11M | -12.6% |
| FY2021 | 2021-12-31 | 694.84M | — |
Sales of Investments vs competitors
How FATE compares with its peers on the latest reported figures
- Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -14.9% is the 4th highest of 10, against a peer median of -45.1%.
- Sales of investments amounts to 4305.9% of revenue for FATE, versus a peer median of 1521.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $459.84M USD | -10.3% | +5.2% | 2496.8% | |
| LTM Mar 2026 | $335.26M USD | +13.7% | +11.1% | — | |
| LTM Mar 2026 | $271.96M USD | -14.9% | -19.9% | 4305.9% | |
| LTM Mar 2026 | $138.92M USD | +29.2% | +11.5% | — | |
| LTM Mar 2026 | $135.28M USD | -45.1% | +28.6% | — | |
| LTM Mar 2026 | CHF 103.25M CHF | -59.1% | -11.6% | — | |
| LTM Mar 2026 | $91.2M USD | -48.9% | -8.9% | 545.4% | |
| LTM Mar 2026 | $82M USD | -28.1% | — | — | |
| LTM Mar 2026 | $24.88M USD | -76.0% | -62.3% | — | |
| LTM Mar 2026 | $18.31M USD | -65.5% | -48.9% | — | |
| Peer median (excluding FATE) | — | -45.1% | -1.8% | 1521.1% | |
Competitors are the stored peer set for FATE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (212.15M) | (281.72M) | (160.93M) | (186.26M) | (136.32M) |
| Depreciation & Amortization | 5.85M | 13.76M | 18.28M | 18.96M | 9.3M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 54.36M | 78.73M | 43.46M | 41.5M | 24.92M |
| Change in Working Capital | 2.1M | (34.71M) | 19.18M | (1.96M) | (3.74M) |
| Accounts Receivables | (3.16M) | (29.8M) | 36.65M | (1.11M) | 2.62M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 14.25M | (28.94M) | (1.66M) | (9.03M) |
| Other Working Capital | 5.26M | (19.16M) | 11.47M | 816K | 2.66M |
| Other Non-Cash Items | (13.03M) | (24.27M) | (52.26M) | 4.89M | (247K) |
| Operating Cash Flow | (162.87M) | (248.21M) | (132.26M) | (122.87M) | (106.08M) |
| Capital Expenditures | (50.7M) | (35.57M) | (6.15M) | (730K) | (5.95M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 362K |
| Purchases of Investments | (968.16M) | (404.8M) | (358.81M) | (317.75M) | (195.14M) |
| Sales of Investments | 694.84M | 607.11M | 477.63M | 330.7M | 311.9M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (324.02M) | 166.75M | 112.67M | 12.22M | 111.17M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 411.74M | 9.21M | 85K | 94.82M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 41.39M | 0 | 0 | 5.07M | 5.49M |
| Financing Cash Flow | 453.13M | 9.21M | 85K | 99.89M | 5.49M |
| Effect of Forex Changes | 0 | 0 | 50K | 4.95M | 0 |
| Net Change in Cash | (33.76M) | (72.25M) | (19.46M) | (5.81M) | 10.57M |
| Free Cash Flow | (213.57M) | (283.77M) | (138.42M) | (123.6M) | (112.04M) |
Fate Therapeutics, Inc.
NASDAQ:FATE
Intrinsic Alpha fair value
Locked
Current Price
$1.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.